{"version":"1.0","provider_name":"Times South Africa","provider_url":"https:\/\/timessouthafrica.com","author_name":"TSA","author_url":"https:\/\/timessouthafrica.com\/author\/tsa\/","title":"Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study - Times South Africa","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"lltE03xWuD\"><a href=\"https:\/\/timessouthafrica.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/\">Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/timessouthafrica.com\/sustained-efficacy-of-long-acting-cabotegravir-for-prep-among-cisgender-women-findings-from-hptn-084-study\/embed\/#?secret=lltE03xWuD\" width=\"600\" height=\"338\" title=\"&#8220;Sustained Efficacy of Long-Acting Cabotegravir for PrEP Among Cisgender Women \u2013 Findings from HPTN 084 Study&#8221; &#8212; Times South Africa\" data-secret=\"lltE03xWuD\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"DURHAM, N.C., July 28, 2022 (GLOBE NEWSWIRE) \u2014 Researchers from the HIV Prevention Trials Network (HPTN) presented updated results from the HPTN 084 long-acting cabotegravir (CAB) for pre-exposure prophylaxis (PrEP) study at the AIDS 2022 conference in Montreal. New findings show reductions in HIV incidence were sustained in the 12 months following trial unblinding (November [\u2026]","thumbnail_url":"https:\/\/ci5.googleusercontent.com\/proxy\/c2SC14aYcNlQCtlHxw5c0-mkDuTu2Ed5hHe4yQmWkVxUArCqu2VZfPmgZ0KL3_XN80eBIv_C8Xqr0WvVIHLeaFOLCBIwEZf6sIk9QFom2zZKO-IjR_rjp4uEHgYHKjQ7=s0-d-e1-ft#https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODYwNzExMSM1MDYwNzEwIzIxOTc2NjY="}